Mabpharm Limited (HK:2181) has released an update.
Mabpharm Limited has announced the approval of their core product, CMAB009 (cetuximab injection), by the National Medical Products Administration of China for use as a first-line therapy for metastatic colorectal cancer in combination with FOLFIRI regimen. This marks the first anti-EGFR monoclonal antibody drug developed in China with independent intellectual property rights to be approved for this purpose. The drug is also expected to be developed for additional cancer indications, signifying a significant step forward in affordable biological targeted cancer treatments in the Chinese market.
For further insights into HK:2181 stock, check out TipRanks’ Stock Analysis page.
